Thiopurine S-Methyltransferase Assay by HPLC in Acute Lymphoblastic Leukemia Patients and a Healthy Iranian Population

  • Sima Mozafari Department of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Nahid Einollahi Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran.
  • Elham Shahgholi Department of Pediatrics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Safoura Vardasbi Department of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Abolfazl Golestani Mail Department of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.


Thiopurine s-methyltransferase (TPMT) plays a key role in the metabolism of the drug; 6-MP in children with acute lymphoblastic leukemia (ALL). The wild-type TPMT*1 allele and mutant alleles are associated with normal and intermediate enzyme activity, respectively. In patients with intermediate or deficient TPMT activity, normal dose of the drug may cause serious side effects such as bone marrow toxicity. The aim of this study was to assay the enzyme activity by HPLC for right ordering of chemotherapy drug doses in the patients. TPMT activity was measured in RBC of healthy adults (n=73) and children (n=10). Also, TPMT (*2, *3A, *3B and *3C) genotype of the samples were assessed by ARMS-PCR and RFLP-PCR. No indication of gender and age differences in the TPMT activity was found. This study showed that the HPLC method was sensitive, accurate and precise and can be used in routine clinical laboratory tests.


Redaelli A, Laskin B, Stephens J, Botteman M, Pashos C. A systematic literature review of the clinical and epidemiological burden of acute lymphoblastic leukaemia (ALL). European journal of cancer care, 2005;14(1):53-62.

Grigoropoulos NF, Petter R, Van‘t Veer MB, Scott MA, Follows GA. Leukaemia update. Part 2: managing patients with leukaemia in the community, 2013.

Wielinga P, Reid G, Challa E, Van der Heijden I, Van Deemter L, De Haas M, et al. Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Molecular Pharmacology, 2002; 62(6):1321-31.

Gale R, Buttunni A. Maintenance chemotherapy and cure of childhood acute lymphoblastic leukaemia. The Lancet, 1991;338 (8778):1315-8.

Gilissen LP, Wong DR, Engels LG, Bierau J, Bakker JA, Paulussen AD, et al. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy. Journal of Crohn's and Colitis, 2012;6 (6):698-707.

Karran P. Thiopurines, DNA damage, DNA repair and therapy-related cancer. British medical bulletin, 2006;79 (1):153-70.

Govani SM, Higgins PD. Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD. Journal of Crohn's and Colitis, 2010;4 (4):444-9.

Seki T, Tanaka T, Nakamura Y. Genomic structure and multiple single-nucleotide polymorphisms (SNPs) of the thiopurine S-methyltransferase (TPMT) gene. Journal of human genetics, 2000; 45(5):299-302.

Schaeffeler E, Fischer C, Brockmeier D, Wernet D, Moerike K, Eichelbaum M, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype–genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics and Genomics, 2004;14 (7):407-17.

Ujiie S, Sasaki T, Mizugaki M, Ishikawa M, Hiratsuka M. Functional characterization of 23 allelic variants of thiopurine S-methyltransferase gene (TPMT*2 - *24). Pharmacogenet Genomics, 2008;18 (10):887-93.

Nguyen CM, Mendes MA, Ma JD. Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk. PLoS currents, 2011;3.

Anglicheau D, Sanquer S, Loriot M-A, Beaune P, Thervet E. Thiopurine methyltransferase activity: new conditions for reversed-phase high-performance liquid chromatographic assay without extraction and genotypic–phenotypic correlation. Journal of Chromatography B. 2002;773 (2):119-27.

Appell ML, Berg J, Duley J, Evans WE, Kennedy MA, Lennard L, et al. Nomenclature for alleles of the thiopurine methyltransferase gene. Pharmacogenetics and genomics, 2013;23 (4):242.

Kader HA, Wenner Jr WJ, Telega GW, Maller ES, Baldassano RN. Normal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease. Journal of clinical gastroenterology, 2000;30 (4):409-13.

von Ahsen N, Chan A. Therapeutic monitoring of immunotherapies in autoimmune diseases. Current pharmaceutical design, 2012;18 (29):4550-5.

Indjova D, Atanasova S, Shipkova M, Armstrong VW, Oellerich M, Svinarov D. Phenotypic and Genotypic Analysis of Thiopurine S‐Methyltransferase Polymorphism in the Bulgarian Population. Therapeutic drug monitoring, 2003;25 (5):631-6.

Khalil MN, Erb N, Khalil PN, Escherich G, Janka-Schaub GE. Interference free and simplyfied liquid chromatography-based determination of thiopurine S-methyltransferase activity in erythrocytes. Journal of Chromatography B. 2005;821(1):105-11.

Hawwa AF, Millership JS, Collier PS, McElnay JC. Development and validation of an HPLC method for the rapid and simultaneous determination of 6-mercaptopurine and four of its metabolites in plasma and red blood cells. Journal of pharmaceutical and biomedical analysis, 2009;49 (2):401-9.

Keizer-Garritsen JJ, Brouwer C, Lambooy LH, Ter Riet P, Bökkerink JP, Trijbels FJ, et al. Measurement of thiopurine S-methyltransferase activity in human blood samples based on high-performance liquid chromatography: reference values in erythrocytes from children. Annals of clinical biochemistry, 2003;40 (1):86-93.

Serpe L, Calvo PL, Muntoni E, D'Antico S, Giaccone M, Avagnina A, et al. Thiopurine S-methyltransferase pharmacogenetics in a large-scale healthy Italian-Caucasian population: differences in enzyme activity. Pharmacogenomics, 2009;10 (11):1753-65.

Chrzanowska M, Kuehn M, Januszkiewicz-Lewandowska D, Kurzawski M, Drozdzik M. Thiopurine S-methyltransferase phenotype-genotype correlation in children with acute lymphoblastic leukemia. Acta Pol Pharm., 2012;69 (3):405-10.

. Azad M, Kaviani S, Soleimani M, Noruzinia M, Hajfathali A. Common polymorphism’s analysis of thiopurine S-methyltransferase (TPMT) in Iranian population. Yakhteh Med J., 2009;11(3):311-6.

Bahari A, Hashemi M, Bari Z, Moazeni-Roodi A, Kaykhaei M-A, Narouie B. Frequency of thiopurine S-methyltransferase (TPMT) alleles in southeast Iranian population. Nucleosides, Nucleotides and Nucleic Acids, 2010; 29(3):237-44.

Elawi AM, Irshaid YM, Ismail SI, Mustafa KN. Thiopurine S-methytransferase Gene Polymorphism in Rheumatoid Arthritis. Archives of medical research, 2013; 44(2):105-9.

Cheung S-p. Genotypic and phenotypic analysis of the thiopurine S-methyltransferase (TPMT) gene with clinical correlation. HKU Theses Online (HKUTO), 2013.

Rossi A, Bianchi M, Guarnieri C, Barale R, Pacifici G. Genotype–phenotype correlation for thiopurine S-methyltransferase in healthy Italian subjects. European journal of clinical pharmacology, 2001;57 (1):51.

Ganiere-Monteil C, Medard Y, Lejus C, Bruneau B, Pineau A, Fenneteau O, et al. Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age. Eur J Clin Pharmacol., 2004;60 (2):89-96.

Zeglam HB, Benhamer A, Aboud A, Rtemi H, Mattardi M, Saleh SS, et al. Polymorphisms of the thiopurine S-methyltransferase gene among the Libyan population. Libyan Journal of Medicine, 2015;10 (1).

How to Cite
Mozafari S, Einollahi N, Shahgholi E, Vardasbi S, Golestani A. Thiopurine S-Methyltransferase Assay by HPLC in Acute Lymphoblastic Leukemia Patients and a Healthy Iranian Population. Acta Med Iran. 56(5):301-307.
Original Article(s)